Home

United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work

via Business Wire

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list.

“We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For,” said Michael Benkowitz, President & Chief Operating Officer of United Therapeutics. “This reflects a key management objective that United Therapeutics be a destination employer, where Unitherians can have their best career while fulfilling our mission to help very sick patients through the development of novel therapeutics and progress toward an unlimited supply of transplantable organs.”

“This achievement is a testament to the commitment of all our employees, the strength of our culture, and the unwavering belief that investing in our people is the key to driving innovation and success,” said Alyssa Friedrich, Executive Vice President and Chief People Officer of United Therapeutics. “We remain focused on creating an environment where everyone feels valued and inspired to bring their best selves to work every day.”

The 100 Best Companies list honors companies that build a high-trust workplace environment, measured through Great Place To Work’s proprietary survey platform. Confidential feedback from more than 1.3 million employees in the U.S. is matched against human resources data from participating companies. Only companies with consistently high survey responses across the 60 statements that comprise the Trust Index™ Survey are honored with placement on the list.

The Fortune 100 Best Companies to Work For list is highly competitive. Companies are only considered for the list if they are a Great Place to Work Certified™ organization with 1,000 or more employees in the U.S. Companies are assessed on their ability to create a great employee experience.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 2, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Contacts